For the past year, there has been a huge buzz about the so-called "weight loss injection". This is supposed to help people ...

The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

Amgen (NASDAQ: AMGN) recently released clinical results for its developmental weight loss drug MariTide. Shares fell by as ...

We recently published a list of 12 Best Affordable Stocks To Buy Right Now. In this article, we are going to take a look at ...

With that let’s take a look at the 12 best affordable stocks to buy right now.

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price ...

Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

Eli Lilly ( NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight ...

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than ...

Furthermore, the biotech's dividend program remains compelling despite near-term headwinds. Therefore, Amgen's combination of ...